Charles River Laboratories (CRL)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$288.50-1.65%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
Charles River Laboratories grows revenue despite a tough market, with 1.2% growth last quarter. The company expects EPS near $11.3 in 2026 and repurchased $200 million of stock in Q1. Its M&A strategy supports growth and portfolio focus. Profitability is improving with positive earnings surprises.
Revenue is expected to decline about 1% in 2026. The company faces regulatory and litigation risks. Profit margins and earnings could weaken if growth falters or divestitures disrupt operations. Stock valuation is high relative to current growth trends.
The stock price is about 14% above our valuation level and 9% below the Street median. Analysts expect revenue to decline about 2% next year. Our view is more cautious on growth but aligned with the market on earnings.
Breaks if: EPS falls below $10.8 in FY26
Breaks if: YoY revenue growth falls below -1.5% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is in a strong-performing company within the healthcare sector, which is currently experiencing favorable conditions. However, the elevated risk and mixed management execution indicate a cautious outlook for the multi-year thesis.
The market appears to have priced in a justified valuation, reflecting strong recent earnings and a low fragility tier. However, the company's premium valuation compared to peers suggests that expectations are somewhat elevated.
Fundamentals are likely to show robust earnings quality, but recent revenue declines indicate challenges in certain segments. Management's focus on divestitures and stock repurchases is on track, yet organic growth remains flat, suggesting limited immediate impact.
The thesis hinges on management's ability to execute on its priorities, particularly in refining the portfolio and enhancing client experience. Additionally, external factors such as sector performance and economic conditions will play a significant role in shaping future results.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the thesis. The company is enhancing its client experience and scientific portfolio through vaccine development. It is also completing divestitures to refine its portfolio. There are no new threats to the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on strengthening client relationships and expanding scientific capabilities to capture more R&D spending.
Stated as a priority in 3 of last 4 quarters. Management highlighted collaborations and AI-enabled solutions to deepen client relationships and enhance the scientific portfolio. While revenue showed modest organic growth in some segments, overall organic revenue was flat to slightly negative, indicating ongoing efforts with limited broad revenue impact so far.
“Joined Eli Lilly's TuneLab AI/ML platform and collaborated with Arovella Therapeutics to enhance client relationships and scientific portfolio.”
“Focus remains on enhancing clients' experience and strengthening scientific portfolio to increase long-term shareholder value.”
“Making significant progress on strategic initiatives to capitalize on growth opportunities and reinforce leadership in preclinical drug development.”
Breaks if: Stock repurchases fall significantly below $200 million in Q1 2026
Over the next 1 to 3 years, CRL's performance will depend on effective management execution and favorable sector trends. Not investment advice.